Paragon Biosciences
Overview
Paragon Biosciences is a life science investment firm that creates, builds, and funds innovative biology-based companies focused on cell and gene therapy, adaptive biology, and advanced biotechnology.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| eMed | Mar 2026 | Series A | Co-investor |
| Castle Creek Biosciences | Feb 2025 | Debt | Co-investor |
| CiRC Biosciences | Feb 2021 | Seed | Lead |
| Evozyne | Sep 2023 | Series B | Co-investor |
For institutional investors. Book with your work email.
Key People
Jeffrey Aronin
Chairman and CEO
Spiro Katerinis
Chief Technology Officer
David Brill
Senior Vice President, Portfolio Management
Cole Ikkala
Vice President, Strategic Capital
Sietse Jonkman
Vice President, Portfolio Management
Fran Subotic
Director of Accounting Operations
Simone B.
Director, Finance
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Paragon Biosciences based?
Paragon Biosciences is headquartered in Chicago, Illinois, United States.
When was Paragon Biosciences founded?
Paragon Biosciences was founded in 2017.
How many portfolio companies does Paragon Biosciences have?
Paragon Biosciences has 5 portfolio companies in Caplight's dataset.
What are some companies in Paragon Biosciences's portfolio?
Portfolio companies visible on Caplight include eMed, Castle Creek Biosciences, CiRC Biosciences, Evozyne.
What was Paragon Biosciences's most recent investment shown here?
Paragon Biosciences's most recent investment in this portfolio sample was in eMed in 2026.
What sectors does Paragon Biosciences focus on?
Paragon Biosciences focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Paragon Biosciences focus on?
Paragon Biosciences typically invests at the MultiStage stage.
What is Paragon Biosciences's AUM?
Paragon Biosciences's assets under management are estimated between $500.0M and $1.0B.